Skip to main content

Applications are now open for the MedCity-Spex Capital Investment Call

MedCity and investment firm Spex Capital have opened their first joint call as part of their exclusive partnership to identify and fund the next generation of digital health and medtech innovators.

Applications are invited from early-stage healthtech ventures with solutions to problems faced by healthcare systems globally. The call closes at midnight on 27th October 2021. 

READ THE FAQ ON HOW TO APPLY

GO TO THE APPLICATION PORTAL

QUESTIONS? EMAIL: [email protected] 

OUR INVESTMENT CALL

MedCity has partnered with Spex Capital to source, evaluate and fund early-stage healthtech ventures and accelerate their route to commercialisation. This exclusive partnership will support several calls for innovative companies seeking investment over the next two years.

The call is targeted at innovative health tech companies seeking Seed or Series A investment. Spex Capital will look to invest up to a max of £5 million per target company. The average ticket is expected to between £500k and £2 million but smaller tickets will be welcome. Successful applicants will also benefit from access to advisory teams with deep sector experience. 

Leading from the MedCity side to source and evaluate viable candidates are COO Nicki Bromwich and Programme Lead Sakura Holloway. Nicki Bromwich has 30 years’ experience as a clinician in the NHS and served as Head of Commercial Development at Oxford AHSN before joining MedCity. Sakura Holloway is an IP and commercial strategist in the biotech sector with a technical background in molecular biology.

 

 

ABOUT SPEX CAPITAL

Founded in 2021 by serial healthtech entrepreneur Claudio D’Angelo, London-based Spex Capital already has a portfolio of six high-growth digital health and medtech companies. The venture firm launched with a team of sixteen, comprising seven investment team members, seven senior advisors and two venture partners. Founder and managing director Claudio D’Angelo leads the call from the Spex Capital side together with senior investment team member Filippo Falaschi.  

READ OUR INTERVIEW WITH CLAUDIO D’ANGELO

Contact us